McKesson and CD&R near $5bn-plus deal to buy infusion services provider
- McKesson and private equity giant CD&R lead $5B bid for Option Care Health
- Option Care handles 315,000 patients annually for complex cancer and autoimmune meds
- Deal structure gives CD&R 51% stake with McKesson holding option to buy the rest
- Consolidation spree continues as drug giants race to own the home-infusion pipeline
Brief Summary
Healthcare behemoth McKesson is teaming up with private equity firm Clayton Dubilier & Rice to swallow Option Care Health in a deal valued at over $5 billion. Option Care, the nation's largest independent provider of home infusion services, has been a goldmine for investors as drugmakers shift toward complex biologics that require specialized administration. The move allows McKesson to tighten its grip on the oncology and specialty drug supply chain, effectively controlling the medicine from the warehouse all the way to the patient's living room.
Why This Matters
When massive drug distributors and private equity firms merge, the cost of specialized care rarely goes down for the end user. As these conglomerates consolidate the infrastructure for life-saving treatments like chemotherapy and autoimmune therapies, you face fewer choices and less leverage in the healthcare market. Expect the trend of 'at-home' care to be pushed aggressively as a cost-saving measure for insurers, while the corporations behind the curtain consolidate their power over the delivery of essential, high-priced medications.